



## RETURN BIDS TO:

## RETOURNER LES SOUMISSIONS À:

Bid Receiving - PWGSC / Réception des soumissions  
- TPSGC

11 Laurier St. / 11, rue Laurier

Place du Portage, Phase III

Core 0B2 / Noyau 0B2

Gatineau, Québec K1A 0S5

Bid Fax: (819) 997-9776

## Revision to a Request for a Standing Offer

## Révision à une demande d'offre à commandes

National Master Standing Offer (NMSO)

Offre à commandes principale et nationale (OCPN)

The referenced document is hereby revised; unless otherwise indicated, all other terms and conditions of the Offer remain the same.

Ce document est par la présente révisé; sauf indication contraire, les modalités de l'offre demeurent les mêmes.

## Comments - Commentaires

## Vendor/Firm Name and Address

Raison sociale et adresse du  
fournisseur/de l'entrepreneur

## Issuing Office - Bureau de distribution

Drugs, Vaccines and Biologics Division/Div.des produits  
pharmaceutiques,biologiques et de vaccins  
11 Laurier St. / 11, rue Laurier  
6B3, Place du Portage III  
Gatineau  
Quebec  
K1A 0S5

<b>Title - Sujet</b> Prime Vendor Standing Offer	
<b>Solicitation No. - N° de l'invitation</b> E60PH-16PVSO/A	<b>Date</b> 2016-03-30
<b>Client Reference No. - N° de référence du client</b> E60PH-16PVSO	<b>Amendment No. - N° modif.</b> 001
<b>File No. - N° de dossier</b> ph893.E60PH-16PVSO	<b>CCC No./N° CCC - FMS No./N° VME</b>
<b>GETS Reference No. - N° de référence de SEAG</b> PW-\$\$PH-893-70693	
<b>Date of Original Request for Standing Offer</b> 2016-03-23	
<b>Date de la demande de l'offre à commandes originale</b>	
<b>Solicitation Closes - L'invitation prend fin</b> <b>at - à 02:00 PM</b> <b>on - le 2016-04-29</b>	
<b>Time Zone</b> <b>Fuseau horaire</b> Eastern Daylight Saving Time EDT	
<b>Address Enquiries to: - Adresser toutes questions à:</b> Vettoretti(ph893), Eric	<b>Buyer Id - Id de l'acheteur</b> ph893
<b>Telephone No. - N° de téléphone</b> (819) 420-2962 ( )	<b>FAX No. - N° de FAX</b> (819) 956-7340
<b>Delivery Required - Livraison exigée</b>	
<b>Destination - of Goods, Services, and Construction:</b> <b>Destination - des biens, services et construction:</b>	
<b>Security - Sécurité</b> This revision does not change the security requirements of the Offer. Cette révision ne change pas les besoins en matière de sécurité de la présente offre.	

Instructions: See Herein

Instructions: Voir aux présentes

<b>Acknowledgement copy required</b> <b>Accusé de réception requis</b>	<b>Yes - Oui</b> <input type="checkbox"/>	<b>No - Non</b> <input type="checkbox"/>
<b>The Offeror hereby acknowledges this revision to its Offer.</b> <b>Le proposant constate, par la présente, cette révision à son offre.</b>		
<b>Signature</b>	<b>Date</b>	
Name and title of person authorized to sign on behalf of offeror. (type or print) Nom et titre de la personne autorisée à signer au nom du proposant. (taper ou écrire en caractères d'imprimerie)		
<b>For the Minister - Pour le Ministre</b>		

---

**Solicitation Amendment #001 is raised to answer the following question regarding the RFSO:**

Q1) I am reviewing the documentation for the above mentioned solicitation. I would like to confirm that this solicitation is for wholesalers who can provide the vast majority of drugs listed in Appendix 4 – Federal Drug List, as opposed to the individual manufacturers of products listed in this appendix.

A1) Yes, this is correct. This requirement is for the services of a national distributor/wholesaler that can provide as a minimum 90% of all products (both brand name and generic drugs) as opposed to individual companies that can provide only their own products identified in Appendix 4. In accordance with mandatory requirement “M.3 – Product Availability” (page 33 of 84), companies that cannot provide at least 90% of the products identified in Appendix 4 will result in their proposal being deemed non-responsive, and the proposal will be given no further consideration.

**All other terms and conditions remain unchanged.**